相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Ye-Xuan Cao et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2019)
Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention
Maximilian Tscharre et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Stefano Spolitu et al.
CIRCULATION RESEARCH (2019)
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial
Michael Szarek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy
Marcio H. Miname et al.
JACC-CARDIOVASCULAR IMAGING (2019)
Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification
Xi Zhao et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2018)
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
Petra El Khoury et al.
DIABETES OBESITY & METABOLISM (2018)
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study
Di Sun et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia
Ye-Xuan Cao et al.
ATHEROSCLEROSIS (2018)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca et al.
CIRCULATION (2018)
Clinical Genetic Testing for Familial Hypercholesterolemia
Amy C. Sturm et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease
Ye-Xuan Cao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography
Jian-Jun Li et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia
Martine Paquette et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Camilla Gustafsen et al.
NATURE COMMUNICATIONS (2017)
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2016)
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Rodrigo Alonso et al.
ATHEROSCLEROSIS (2016)
PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
Nicola Ferri et al.
ATHEROSCLEROSIS (2016)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Cardiovascular risk stratification in familial hypercholesterolaemia
Mahtab Sharifi et al.
HEART (2016)
Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
Sha Li et al.
ANNALS OF MEDICINE (2015)
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
Yiming M. Zhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease A Prospective Observational Cohort Study
Jian-Jun Li et al.
MEDICINE (2015)
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype
Jean-Philippe Drouin-Chartier et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers
Joost Besseling et al.
ATHEROSCLEROSIS (2014)
Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort
Afef Slimani et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2014)
Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects
Gilles Lambert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
Christian Werner et al.
VASCULAR PHARMACOLOGY (2014)
Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9
Yuan-Lin Guo et al.
CLINICAL DRUG INVESTIGATION (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
Zuhier Awan et al.
CLINICAL CHEMISTRY (2012)
PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
Zhihan Tang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways
Jamie Cameron et al.
TRANSLATIONAL RESEARCH (2012)
Chronic Alcohol Consumption Disrupted Cholesterol Homeostasis in Rats: Down-Regulation of Low-Density Lipoprotein Receptor and Enhancement of Cholesterol Biosynthesis Pathway in the Liver
Zhigang Wang et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2010)
分享论文
